Haryana govt order for athletes to deposit 1/3rd share of their earnings sparks a row

Mt. Maunganui (New Zealand), Feb 11: KL Rahul struck a combative 112 but New Zealand completed a 3-0 whitewash of India by winning the third ODI by five wickets, here on Tuesday.

Rahul helped India recover from a shaky start to post a challenging 296 for 7 but the Kiwis overhauled the target with 17 balls to spare.

This is the first whitewash that India has suffered in an ODI series in more than a decade.

Sent in to bat, India were down 62 for 3 in the 13th over after the dismissals of Mayank Agarwal (1), captain Virat Kohli (9) and Prithvi Shaw (40) but Rahul got a useful ally in in-form Shreyas Iyer (62) to take India to a competitive total.

Rahul, who hit nine fours and two sixes during his 113-ball innings, and Iyer stitched exactly 100 runs from 18.2 overs for the fourth wicket to revive the Indian innings.

After the end of the promising innings of Iyer, Rahul shared another 107 runs for the fifth wicket with Manish Pandey (42).

The Kiwis were off to a confident start in their chase with Martin Guptill (66) and Henry Nicholls (80) and putting on a 106-run stand. However, wrist spinner Yuzvendra Chahal took three wickets to bring India back in the game.

Colin de Grandhomme (58) and Tom Latham (32), though, took their side past the finish line with an unbeaten 80-run partnership.

Brief Scores:

India: 296 for 7 in 50 overs (KL Rahul 112, Shreyas Iyer 62; Hamish Bennett 4/64).

New Zealand: 300 for 5 in 47.1 overs. (H Nicholls 80, M Guptill 66; Y Chahal 3/47).

New Delhi, Feb 12: The Centre on Wednesday said the NRC data in Assam is safe even though some technical issues were visible and that will be resolved soon.

The Union Home Ministry clarification came in view of reports that data of the final list of the National Register of Citizens has been made offline from its official website.

"The NRC data is safe. Some technical issues are in visibility on cloud. These are being resolved soon," a home ministry spokesperson said.

The data was not available for a couple of days and it created panic in the public, mostly among the people excluded from the list as the rejection certificates were yet to be issued.

NRC State Coordinator Hitesh Dev Sarma accepted that the data has been made offline, but refuted the allegation of any "malafide" intent in it.

The cloud service for the huge set of data was provided by IT firm Wipro and their contract was till October 19 last year. However, this was not renewed by the previous coordinator.

So, the data got offline from December 15 after it was suspended by Wipro, Sarma said.

He said the state coordination committee had decided to do necessary formalities in its meeting on January 30 and wrote to the Wipro during the first week of February.

"Once Wipro makes the data live, it will be available for public. We hope people will be able to access it in the next 2-3 days," Sarma said.

The complete detail of exclusion and inclusion of bonafide Indian citizens in the NRC was uploaded on its official website http://www.nrcassam.nic.in after the final list was published on August 31, 2019.

The final NRC was published by excluding 19,06,657 persons. A total of 3,11,21,004 names were included out of 3,30,27,661 applicants.

After the earlier NRC State Coordinator Prateek Hajela relinquished the charge on November 11 following his transfer to home state Madhya Pradesh on a direction from the Supreme Court, Sarma was appointed in his place on November 9.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.